首页   按字顺浏览 期刊浏览 卷期浏览 Systemic Administration of Interleukin‐2 in Humans
Systemic Administration of Interleukin‐2 in Humans

 

作者: Michael Lotze,   Richard Robb,   Susan Sharrow,   Lesley Frana,   Steven Rosenberg,  

 

期刊: Journal of Biological Response Modifiers  (OVID Available online 1984)
卷期: Volume 3, issue 5  

页码: 475-482

 

ISSN:0732-6580

 

年代: 1984

 

出版商: OVID

 

关键词: Interleukin‐2;JURKAT T cell tumor;Lymphokine‐activated killer;T cells.

 

数据来源: OVID

 

摘要:

Summary:Twelve patients were treated in a Phase I trial of purified human interleukin‐2 (IL‐2) derived from the JURKAT cell line (E. I. duPont Corp., Glenolden, PA, U.S.A.). The serum half‐life, toxicity, andin vivoimmunologic effects of IL‐2 were studied in patients with cancer unresponsive to standard therapy and in patients with acquired immunodeficiency syndrome (AIDS). Patients received 0.25, 2.5, or 25 &mgr;g/kg IL‐2 by bolus or 24‐h continuous infusion on a weekly basis for 4 weeks. The serum half‐life of JURKAT IL‐2 in humans was ˜ 6 min. At higher doses of IL‐2 a second component of clearance with a half‐life of 30‐120 min was found. Acute toxicity was minimal and consisted of headache (6 of 12), nausea (4 of 12), malaise (6 of 12), and fever and chills (8 of 12). No evidence of pulmonary, hematologic, or renal toxicity or any evidence of autoimmune phenomena was detected. A transient hyperbilirubinemia was seen in two patients receiving 2 mg purified IL‐2. No demonstrable effect on tumors or chronic immunodeficiency (AIDS) was seen. No consistent chronic immunologic effects (natural killer or lymphokine‐activated killer activity, mitogen responsiveness, total lymphocyte counts, or change in the proportion of various mononuclear cell phenotypes as defined by monoclonal antibody) were seen on a week‐to‐week basis during or following therapy. Acute changes in lymphokine responsiveness, the ability to generate lymphokine‐activated killers, and an increase in macrophages in the mononuclear population were noted following administration of 1‐2 mg IL‐2.

 

点击下载:  PDF (3526KB)



返 回